Receptor for hyaluronan‐mediated motility ( RHAMM ) defines an invasive niche associated with tumor progression and predicts poor outcomes in breast cancer patients
The Journal of Pathology · 2023
DOI: 10.1002/path.6082 ↗At a glance
Journal article in The Journal of Pathology, 2023. Written by Sarah E Tarullo and 23 co-authors. Institution: Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA. Major MEDLINE topics: Breast Neoplasms. Cited 21 times so far (Crossref); 71 references. The full text is freely available (open access, CC BY 4.0). Funded by: NIGMS NIH HHS, NCI NIH HHS, NCATS NIH HHS.
Topics: Onkologische Pflege
Abstract (original language)
Breast cancer invasion and metastasis result from a complex interplay between tumor cells and the tumor microenvironment (TME). Key oncogenic changes in the TME include aberrant synthesis, processing, and signaling of hyaluronan (HA). Hyaluronan‐mediated motility receptor (RHAMM, CD168; HMMR ) is an HA receptor enabling tumor cells to sense and respond to this aberrant TME during breast cancer progression. Previous studies have associated RHAMM expression with breast tumor progression; however, cause and effect mechanisms are incompletely established. Focused gene expression analysis of an internal breast cancer patient cohort confirmed that increased RHAMM expression correlates with aggressive clinicopathological features. To probe mechanisms, we developed a novel 27‐gene RHAMM‐related signature (RRS) by intersecting differentially expressed genes in lymph node (LN)‐positive patient cases with the transcriptome of a RHAMM‐dependent model of cell transformation, which we validated in an independent cohort. We demonstrate that the RRS predicts for poor survival and is enriched for cell cycle and TME‐interaction pathways. Further analyses using CRISPR/Cas9‐generated RHAMM −/− breast cancer cells provided direct evidence that RHAMM promotes invasion in vitro and in vivo . Immunohistochemistry studies highlighted heterogeneous RHAMM protein expression, and spatial transcriptomics associated the RRS with RHAMM‐high microanatomic foci. We conclude that RHAMM upregulation leads to the formation of ‘invasive niches’, which are enriched in RRS‐related pathways that drive invasion and could be targeted to limit invasive progression and improve patient outcomes. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.
- Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
- Minnesota Supercomputing Institute, University of Minnesota, Minneapolis, MN, USA.
- London Health Sciences Center, Western University, Ontario, Canada.
- School of Medicine, University of Minnesota, Minneapolis, MN, USA.
- Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
ORCID profiles: Todd P Knutson, Rachael E Kaspar, Andrew C Nelson
Funding
- NIGMS NIH HHS
- NCI NIH HHS
- NCATS NIH HHS
- NICHD NIH HHS
- American Cancer Society
- Breast Cancer Society of Canada
- National Cancer Institute
- National Institute of General Medical Sciences
Cite
APA
Tarullo, S. E., He, Y., Daughters, C., Knutson, T. P., Henzler, C. M., Price, M. A., Shanley, R., Witschen, P., Tolg, C., Kaspar, R. E., Hallstrom, C., Gittsovich, L., Sulciner, M. L., Zhang, X., Forster, C. L., Lange, C. A., Shats, O., Desler, M., Cowan, K. H., …, & Nelson, A. C. (2023). Receptor for hyaluronan‐mediated motility ( RHAMM ) defines an invasive niche associated with tumor progression and predicts poor outcomes in breast cancer patients. The Journal of Pathology. https://doi.org/10.1002/path.6082
Vancouver
Tarullo SE, He Y, Daughters C, Knutson TP, Henzler CM, Price MA, et al. Receptor for hyaluronan‐mediated motility ( RHAMM ) defines an invasive niche associated with tumor progression and predicts poor outcomes in breast cancer patients. The Journal of Pathology. 2023. doi:10.1002/path.6082
BibTeX
@article{Tarullo2023,
author = {Tarullo, Sarah E and He, Yuyu and Daughters, Claire and Knutson, Todd P and Henzler, Christine M and Price, Matthew A and Shanley, Ryan and Witschen, Patrice and Tolg, Cornelia and Kaspar, Rachael E and Hallstrom, Caroline and Gittsovich, Lyubov and Sulciner, Megan L and Zhang, Xihong and Forster, Colleen L and Lange, Carol A and Shats, Oleg and Desler, Michelle and Cowan, Kenneth H and Yee, Douglas and Schwertfeger, Kathryn L and Turley, Eva A and McCarthy, James B and Nelson, Andrew C},
title = {Receptor for hyaluronan‐mediated motility ( RHAMM ) defines an invasive niche associated with tumor progression and predicts poor outcomes in breast cancer patients},
journal = {The Journal of Pathology},
year = {2023},
doi = {10.1002/path.6082}
}
EUVIMED